US equities |
MU $1,046.06 ▼-1.79% NVDA $230.42 ▲+0.89% SNDK $1,739.25 ▼-0.04% TSLA $356.24 ▲+0.40% INTC $119.49 ▼-0.62% SPCX $151.16 ▲+0.20% GOOGL $339.80 ▼-1.24% AMD $611.08 ▼-0.11%
FinancialContent Watchlist

Articles published by CAMP4 Therapeutics

News headline image
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
News headline image
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP